Interferon-free regimens in patients with hepatitis C infection and renal dysfunction or kidney transplantation

Table 3 Studies of interferon-free regimens for treatment of hepatitis C virus positive kidney transplant recipients

Ref.	Patients, n	Patient characteristics	Regimen: Patients number	Sustained virological response at 12 wk, n/N	Adverse events, n
Huard et al[39]	17	GT1: 16 patients (1a: 5) Age: 65 yr	SOF + RBV: 17 (400 mg/d)	1/6	Therapy discontinuation: 4 (3 due to pruritus, myalgia, anemia, 1 unclarified) Anemia: 8
Lin et al[40]	15	GT1: 14 (1a: 10) Age: 55.8 yr	SOF + SMV ± RBV: 12 (SOF + SMV: 9)	13/15	No serious adverse events under therapy (1 died by massive hemorrhage 4 wk after therapy) Proteinuria: 2
			SOF + RBV: 2 SOF + LDV: 1		Bradycardia under amiodarone (pacemaker placement): 1
Bhamidimarri et al[41]	14	GT1: 14 (1a: 12)	SOF + LDV: 13	13/14	No serious adverse events
		Age: 54 yr	(in 9 plus RBV)		Therapy discontinuation: 1
			SOF + SMV: 1		Anemia: 7
Hussein et al[42]	3	GT4: 3	SOF + RBV	3/3	No serious adverse events
			(400 mg/d)
Sawinski et al[43]	20	GT1: 17 (1a: 7)	SOF + SMV: 9	20/20	No serious adverse events
		Age: 57 yr	SOF/LDV: 7
			SOF + RBV: 3
			SOF + DCV: 1
			(400 mg/d)
Moreno et al[44]	12	GT1: 11 (1a: 4)	SOF + SMV: 1	11/12	Therapy discontinuation: 1
		Age: 53 yr	SOF/LDV: 8
			SOF + DCV: 3
			(400 mg/d)
El-Halawany et al[45]	11	GT1: 10 (1a: 10)	SOF + SMV: 2	10/11	No serious adverse events
		Age: 57.6 yr	SOF/LDV: 8
			SOF + RBV: 1
Londono et al[46]	74	GT1: 61 (1a: 6)	SOF/LDV ± RBV: 37	45/46	Rejection episodes: 3
		Age: 54 yr	SOF + DCV ± RBV: 15
			SOF + SMV ± RBV: 6
			SMV + DCV ± RBV: 7
			SOF + RBV: 4
			3 “D” or 2 “D”: 5
Colombo et al[47]	114	GT1: 104	SOF/LDV	112/114	Therapy discontinuation: 1
					Serious adverse events: 12
Reddy et al[48]	50		SOF/LDV ± RBV: 42	10/10	Rejection episode: 1
			SOF + DCV ± RBV: 1
			3 “D”: 7

DCV: Daclatasvir; GT: Genotype; RBV: Ribavirin; LDV: Ledipasvir; PEG-IFN: Pegylated interferon-alfa; SMV: Simeprevir; SOF: Sofosbuvir; 3D: Ombitasvir/paritaprevir/ritonavir plus dasabuvir; 2 “D”: Ombitasvir/paritaprevir/ritonavir.